Sapientia Pharmaceuticals Inc.
SPI will develop novel therapeutics for a severe orphan disease with no approved therapy and estimated peak sales of over $1B
Systemic Sclerosis is a progressive, fibrotic disease with no approved therapies and ~90,000 cases in the US alone. Sapientia Pharmaceuticals has identified small molecules that act on the fibrosis and vasculopathy of SSc. SPI anticipates filing an Investigational New Drug Applications within 2 years with the total time to marketing authorization 7-9 years. Peak year sales in excess of $1-2B are estimated for a small molecule treatment for SSc.